For reprint orders, please contact reprints@future-science.com

How has the genomics era impacted schistosomiasis drug discovery?

“A community effort will almost certainly be necessary for the identification of new lead compounds and therefore information and reagent sharing will be important to ensure that the goals of the schistosomiasis drug research community are achieved.”

Keywords: cheminformatics • drug discovery • genome • schistosomiasis

Schistosomiasis is a chronic neglected tropical disease that can be debilitating, particularly in children and its impact on infected populations is severe [1]. Moreover, infection by *Schistosoma haematobium* is associated with bladder cancer [2]. Currently over 700 million people are at risk of infection with up to 400 million estimated infections [3,4]. There is a need for more sensitive diagnostics to support current mass chemotherapy efforts and elimination trials. It also appears that without a vaccine it will be very difficult to achieve elimination or a high degree of transmission control. Currently, praziquantel is the only drug available for mass treatment; it is an inexpensive drug with very tolerable adverse effects with typical cure rates ranging between 75 and 100%. The drug's mechanism of action is, as yet, not fully understood, but we know that it requires the action of the immune system in concert with tegument damage and paralysis caused by the drug [5]. Drawbacks of this drug are its ineffectiveness toward schistosomula and the lack of a pediatric formulation [6]. In addition, taking into account the use of praziquantel in mass chemotherapy programs, there is a significant risk that drug resistance may develop, an issue that has been widely described for other helminths under strong selective pressure. Since PZQ is the only drug available, the emergence of drug resistance is extremely concerning [7].

The development of new control tools to combat schistosomiasis have for a long time relied on empirical approaches based on little or no knowledge of the targets, and gene-by-gene methods to further the molecular understanding of schistosome

biology have not resulted in a robust pipeline of possible vaccine and drug candidates. Recent developments in genomics have brought forth a wealth of information and new technologies, providing the scientific community with the tools needed to completely revolutionize the experimental and computational approaches for target identification. The community is now empowered by the availability of the genomes of the three main schistosome species of medical importance. In addition, high-throughput methods such as transcriptomics and proteomics have provided interesting insights into the functionality of genomes, and have proven particularly effective in identifying targets that are of interest in the schistosome life cycle stages within the human host. Additionally, a number of new flatworm and roundworm genomes have been made available, which provide a valuable basis for comparative biology, from a genomics perspective. Taking these advances into account, we now have a strong knowledge base to develop new drugs and other novel control tools. Additional information of interest is being generated by several groups concerning the genetic variability of specimens from endemic sites and the genetics of drug resistance. It has been observed that under praziquantel pressure there is decrease in the genetic diversity of a laboratory schistosome population [8]. With the use of linkage mapping the gene coding for sulfotransferase was described as being responsible for resistance to oxamniquine [9]. Recently, the ability to conduct deep exome sequencing and SNP mapping at high resolution has provided a new tool

Guilherme Oliveira

Author for correspondence:
Genomics & Computational Biology
Group, René Rachou Research Center,
Oswaldo Cruz Foundation, Av. Augusto
de Lima 1715, Belo Horizonte,
MG 30190-002, Brazil
oliveira@cpqrr.fiocruz.br

Raymond J Pierce

Center for Infection & Immunity of Lille
(CIIL), INSERM U1019-CNRS UMR 8204,
Université de Lille, Institut Pasteur de
Lille, F-59000 Lille, France

**FUTURE
SCIENCE** part of

fsg

for the identification of genes involved with drug resistance [10]. We anticipate that, in the near future, the genes involved with phenotypes of interest will be identified using these methodologies.

Efforts to explore current genome data have included the use of computational tools for the discovery of novel drug targets and the development of new antischistosomal agents. This has been demonstrated by the Open Source Drug Discovery Consortium, which has identified compounds with activity toward a putative known target, TGR, using machine learning tools and cheminformatics [11].

Computational approaches to neglected disease drug discovery have been enhanced by the availability of resources such as the open access database TDRTargets. By combining predicted protein datasets from genome data with chemical entities derived from public sources, TDRTargets provides researchers with the tools needed to combine queries for protein targets and bioactive compounds. This resource is largely designed to enable drug repositioning and repurposing across different parasite species. For example, using the tools available in TDRTargets, one could query for targets in one organism that shows essentiality in a different species and for which there are known inhibitors, in addition to adding druggability and assayability indices and limiting the results to manually curated compounds [12].

“Overall, the use of public resources, such as those identified above, have enabled researchers to identify and prioritize drug targets...”

Researchers have also used metabolic modeling software, such as Pathway Tools, to study the metabolic pathways in *Schistosoma mansoni* and in turn uncover new drug targets. Pathway Tools is capable of predicting an organism's metabolic pathways from its genome by comparison to MetaCyc, a reference pathways database. In a study that was the first to describe the *S. mansoni* genome, Pathway Tools was used to identify critical points, termed chokepoints, which were demonstrated to be druggable targets [13].

Overall, the use of public resources, such as those identified above, have enabled researchers to identify and prioritize drug targets and, with the huge amounts of genomic data being generated, it is clear that these resources will be essential in helping to accelerate neglected disease drug discovery.

Driving these efforts toward, at the very least, obtaining lead compounds is a challenge, especially for individual research groups. In recent years, strategies to enhance the drug pipeline have been put into place with the establishment of large consortia, such as A-ParaDDisE [14,15]. Such consortia rely on pooling

expertise from a range of disciplines in order to work more effectively toward a common goal. These consortia often involve collaboration with industry, which is arguably essential for creating a successful drug pipeline that will deliver a sufficiently large number of compounds to be tested and decrease the cost of pre-clinical testing. A-ParaDDisE researchers have drawn on the knowledge gained through the development of HMEs as targets in cancer in order to establish these enzymes as targets in schistosomiasis, malaria, leishmaniasis and Chagas disease. HMEs perform covalent modifications of amino acid residues on the N-terminal tails of histones by adding or removing marks, such as methyl or acetyl groups. Histones in turn regulate gene activity by changing chromatin architecture. It has been shown, for example, that deacetylation of histones by HDACs results in tighter wrapping of the DNA, which in turn is associated with the global downregulation of gene transcription. HDACs, in addition to acting on histones, also deacetylate other cytoplasmic proteins. Such activities may be essential in the regulation of the complex schistosome life cycle and enzymes involved in these processes have been shown to be crucial for the growth and differentiation of the parasite [16]. The central role of one HDAC, *SmHDAC8*, was validated using a phenotypic screen by RNAi to knock down gene expression. An active enzyme was produced and structure data derived from a protein crystal, with or without generic inhibitors. With such data, additional new inhibitor structures were proposed using *in silico* tools and new small molecules were produced that were found to be active on live worms in culture [16]. This approach is being pursued, in addition to high-throughput screening, to target other HMEs in schistosomes, such as Sirtuins, and for HMEs of other parasites [17,18].

Target identification and establishing drug candidates in the drug discovery process is a difficult task; however, seeing a candidate drug through the safety and drug metabolism phase, and later to clinical trials is an even greater one. With this in mind, the challenge that we are tasked with is the identification of promising candidate drugs that can successfully navigate the ‘obstacle course’ of toxicology and bioavailability testing and clinical trials and that are inexpensive enough to permit their use in endemic countries.

This special focus issue provides in-depth discussion of the various efforts being undertaken toward populating the schistosomiasis drug development pipeline. A community effort will almost certainly be necessary for the identification of new lead compounds and therefore information and reagent sharing will be important to ensure that the goals of the schistosomiasis drug research community are achieved.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment,

consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

References

- King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. *Lancet* 365(9470), 1561–1569 (2005).
- Gouveia MJ, Santos J, Brindley PJ *et al.* Estrogen-like metabolites and DNA-adducts in urogenital schistosomiasis-associated bladder cancer. *Cancer Lett.* 359(2), S0304–S3835 (2015).
- Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. *Lancet* 368(9541), 1106–1118 (2006).
- King CH. Parasites and poverty: the case of schistosomiasis. *Acta Trop.* 113(2), 95–104 (2010).
- Redman CA, Robertson A, Fallon PG *et al.* Praziquantel: an urgent and exciting challenge. *Parasitol. Today* 12(1), 14–20 (1996).
- Sabah AA, Fletcher C, Webbe G, Doenhoff MJ. *Schistosoma mansoni*: chemotherapy of infections of different ages. *Exp. Parasitol.* 61(3), 294–303 (1986).
- Bennett JL, Day T, Liang FT, Ismail M, Farghaly A. The development of resistance to anthelmintics: a perspective with an emphasis on the antischistosomal drug praziquantel. *Exp. Parasitol.* 87(3), 260–267 (1997).
- Coeli R, Baba EH, Araujo N, Coelho PM, Oliveira G. Praziquantel treatment decreases *Schistosoma mansoni* genetic diversity in experimental infections. *PLoS Negl. Trop. Dis.* 7(12), e2596 (2013).
- Valentim CL, Cioli D, Chevalier FD *et al.* Genetic and molecular basis of drug resistance and species-specific drug action in schistosome parasites. *Science* 342(6164), 1385–1389 (2013).
- Chevalier FD, Valentim CL, LoVerde PT, Anderson TJ. Efficient linkage mapping using exome capture and extreme QTL in schistosome parasites. *BMC Genomics* 15, 617 (2014).
- Gaba S, Jamal S, Scaria V. Open Source Drug Discovery Consortium. Cheminformatics models for inhibitors of *Schistosoma mansoni* thioredoxin glutathione reductase. *Scientific World J.* 2014, 957107 (2014).
- Crowther GJ, Shanmugam D, Carmona SJ *et al.* Identification of attractive drug targets in neglected-disease pathogens using an in silico approach. *PLoS Negl. Trop. Dis.* 4(8), e804 (2010).
- Berriman M, Haas BJ, LoVerde PT *et al.* The genome of the blood fluke *Schistosoma mansoni*. *Nature* 460(7253), 352–358 (2009).
- Pierce RJ, Dubois-Abdesselem F, Lancelot J, Andrade L, Oliveira G. Targeting schistosome histone modifying enzymes for drug development. *Curr. Pharm. Des.* 18(24), 3567–3578 (2012).
- Anti-parasitic drug discovery in epigenetics. <http://a-paradise.cebio.org/>
- Marek M, Kannan S, Hauser AT *et al.* Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke *Schistosoma mansoni*. *PLoS Pathog.* 9(9), e1003645 (2013).
- Lancelot J, Caby S, Dubois-Abdesselem F *et al.* *Schistosoma mansoni* Sirtuins: characterization and potential as chemotherapeutic targets. *PLoS Negl. Trop. Dis.* 7(9), e2428 (2013).
- Cabezas-Cruz A, Lancelot J, Caby S, Oliveira G, Pierce RJ. Epigenetic control of gene function in schistosomes: a source of therapeutic targets? *Front Genet.* 5, 317 (2014).